Synthesis of [14C]boceprevir, [13C3]boceprevir, and [D9]boceprevir, a hepatitis C virus protease inhibitor

Ren, S., Royster, P., Lavey, C., Hesk, D., McNamara, P., Koharski, D., Truong, V., & Borges, S. (2012). Synthesis of [14C]boceprevir, [13C3]boceprevir, and [D9]boceprevir, a hepatitis C virus protease inhibitor. Journal of Labelled Compounds and Radiopharmaceuticals, 55(3), 108-114. https://doi.org/10.1002/jlcr.1960

Abstract

Boceprevir is a hepatitis C virus (HCV) NS3 protease inhibitor for HCV treatment. [14C]Boceprevir (SCH 503034, trade name Victrelis) was synthesized from K14CN in 11 steps with an overall yield of 16.4%. [13C3]Boceprevir was synthesized in 16 steps with a 2.5% overall yield. The carbon-13 in the molecule was distributed along the peptide chain. [D9]Boceprevir was synthesized from [D9]-t-butylamine in four steps with an overall yield of 69%. Copyright (C) 2012 John Wiley & Sons, Ltd.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Article

Nitric oxide-releasing hemodialysis catheter lock solutions
Article

Matrix matters
Article

Long-term effects of a diet supplement containing Cannabis sativa oil and Boswellia serrata in dogs with osteoarthritis following physiotherapy treatments